Tags

Type your tag names separated by a space and hit enter

Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea.
J Clin Med. 2020 Jun 23; 9(6)JC

Abstract

A rapid increase in the number of patients with coronavirus disease 19 (COVID-19) may overwhelm the available medical resources. We aimed to evaluate risk factors for disease severity in the early stages of COVID-19. The cohort comprised 293 patients with COVID-19 from 5 March 2020, to 18 March 2020. The Korea Centers for Disease Control and Prevention (KCDC) classification system was used to triage patients. The clinical course was summarized, including the impact of drugs (angiotensin II receptor blockers [ARB], ibuprofen, and dipeptidyl peptidase-4 inhibitors [DPP4i]) and the therapeutic effect of lopinavir/ritonavir. After adjusting for confounding variables, prior history of drug use, including ARB, ibuprofen, and DPP4i was not a risk factor associated with disease progression. Patients treated with lopinavir/ritonavir had significantly shorter progression-free survival than those not receiving lopinavir/ritonavir. KCDC classification I clearly distinguished the improvement/stabilization group from the progression group of COVID-19 patients (AUC 0.817; 95% CI, 0.740-0.895).

Authors+Show Affiliations

Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 06273, Korea. Department of Laboratory Medicine, Armed Forces Daegu Hospital, Daegu 712-906, Korea.Department of Ophthalmology, Armed Forces Daegu Hospital, Daegu 712-906, Korea.Department of Internal Medicine, Armed Forces Daegu Hospital, Daegu 712-906, Korea.Department of Internal Medicine, Armed Forces Daegu Hospital, Daegu 712-906, Korea.Department of Internal Medicine, Armed Forces Daegu Hospital, Daegu 712-906, Korea.Department of Internal Medicine, Armed Forces Daegu Hospital, Daegu 712-906, Korea.Department of Internal Medicine, Armed Forces Daegu Hospital, Daegu 712-906, Korea.Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 06273, Korea.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32585855

Citation

Choi, Min Hyuk, et al. "Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea." Journal of Clinical Medicine, vol. 9, no. 6, 2020.
Choi MH, Ahn H, Ryu HS, et al. Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea. J Clin Med. 2020;9(6).
Choi, M. H., Ahn, H., Ryu, H. S., Kim, B. J., Jang, J., Jung, M., Kim, J., & Jeong, S. H. (2020). Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea. Journal of Clinical Medicine, 9(6). https://doi.org/10.3390/jcm9061959
Choi MH, et al. Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea. J Clin Med. 2020 Jun 23;9(6) PubMed PMID: 32585855.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea. AU - Choi,Min Hyuk, AU - Ahn,Hyunmin, AU - Ryu,Han Seok, AU - Kim,Byung-Jun, AU - Jang,Joonyong, AU - Jung,Moonki, AU - Kim,Jinuoung, AU - Jeong,Seok Hoon, Y1 - 2020/06/23/ PY - 2020/06/03/received PY - 2020/06/19/revised PY - 2020/06/19/accepted PY - 2020/6/27/entrez PY - 2020/6/27/pubmed PY - 2020/6/27/medline KW - Korea centers for disease control and prevention (KCDC) classification KW - angiotensin II receptor blockers (ARB) KW - coronavirus disease-19 (COVID-19) KW - ibuprofen KW - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) JF - Journal of clinical medicine JO - J Clin Med VL - 9 IS - 6 N2 - A rapid increase in the number of patients with coronavirus disease 19 (COVID-19) may overwhelm the available medical resources. We aimed to evaluate risk factors for disease severity in the early stages of COVID-19. The cohort comprised 293 patients with COVID-19 from 5 March 2020, to 18 March 2020. The Korea Centers for Disease Control and Prevention (KCDC) classification system was used to triage patients. The clinical course was summarized, including the impact of drugs (angiotensin II receptor blockers [ARB], ibuprofen, and dipeptidyl peptidase-4 inhibitors [DPP4i]) and the therapeutic effect of lopinavir/ritonavir. After adjusting for confounding variables, prior history of drug use, including ARB, ibuprofen, and DPP4i was not a risk factor associated with disease progression. Patients treated with lopinavir/ritonavir had significantly shorter progression-free survival than those not receiving lopinavir/ritonavir. KCDC classification I clearly distinguished the improvement/stabilization group from the progression group of COVID-19 patients (AUC 0.817; 95% CI, 0.740-0.895). SN - 2077-0383 UR - https://www.unboundmedicine.com/medline/citation/32585855/Clinical_Characteristics_and_Disease_Progression_in_Early-Stage_COVID-19_Patients_in_South_Korea L2 - https://www.mdpi.com/resolver?pii=jcm9061959 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.